A5100340659- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Research on Leishmaniasis Studies
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Glycosylation and Glycoproteins Research
- Ubiquitin and proteasome pathways
- Signaling Pathways in Disease
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Radiomics and Machine Learning in Medical Imaging
- Visual perception and processing mechanisms
- HER2/EGFR in Cancer Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Cancer Genomics and Diagnostics
- Hematopoietic Stem Cell Transplantation
- Platelet Disorders and Treatments
- Mesenchymal stem cell research
- Ophthalmology and Visual Impairment Studies
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Ophthalmology and Eye Disorders
Xiyuan Hospital
2025
Tianjin Medical University Cancer Institute and Hospital
2016-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2009-2025
National Clinical Research
2021-2024
Sichuan University
2023
West China Hospital of Sichuan University
2023
Wenzhou Medical University
2018-2022
First Affiliated Hospital of Wenzhou Medical University
2022
Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University
2018-2022
University of California, Davis
2018
Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cancer precursors incidentally discovered by cross-sectional imaging. Consensus guidelines for IPMN management rely on standard radiologic features to predict pathology, but they lack accuracy. Using a retrospective cohort of 38 surgically-resected, pathologically-confirmed IPMNs (20 benign; 18 malignant) with preoperative computed tomography (CT) images and matched plasma-based 'miRNA genomic classifier (MGC)' data, we...
Development of chemoresistance is the main reason for failure clinical management multiple myeloma (MM), but genetic and epigenetic aberrations that interact to confer such remains unknown. In present study, we find high steroid receptor coactivator-3 (SRC-3) expression correlated with relapse/refractory poor outcomes in MM patients treated bortezomib (BTZ)-based regimens. Furthermore, immortalized cell lines, SRC-3 enhances resistance proteasome inhibitor (PI)-induced apoptosis....
High-grade serous ovarian cancer (HGSOC), the predominant subtype of epithelial cancer, is frequently diagnosed at an advanced stage due to its nonspecific early symptoms. Despite standard treatments, including cytoreductive surgery and platinum-based chemotherapy, significant improvements in survival have been limited. Understanding molecular mechanisms, immune landscape, drug sensitivity HGSOC crucial for developing more effective personalized therapies. This study integrates insights from...
Accumulating evidence indicates that intratumor heterogeneity is prevalent in multiple myeloma and a collection of multiple, genetically distinct subclones are present within the cell population. It not clear whether size clonal populations harboring unique cytogenetic abnormalities carry any additional prognostic value.We analyzed impact aberrations by fluorescence situ hybridization at different cutoff values cohort 333 patients with newly diagnosed 92 relapsed myeloma.We found nearly all...
Background Immunotherapies targeting CD38 have demonstrated salient efficacy in relapsed/refractory multiple myeloma (MM). However, loss of antigen and outgrowth negative plasma cells emerged as a major obstacle clinics. All-trans retinoic acid (ATRA) has been reported to upregulate expression, but the mechanism adaptive genetic background remain unexplored. Methods The ATRA upregulating expression MM is evaluated by flow cytometry. interaction between NSD2 RARα analyzed immunoprecipitation,...
The chromosomal t(4;14) (p16;q32) translocation drives high expression of histone methyltransferase nuclear SET domain-containing 2 (NSD2) and plays vital roles in multiple myeloma (MM) evolution progression. However, the mechanisms NSD2-driven epigenomic alterations chemoresistance to proteasome inhibitors (PIs) are not fully understood. Using a CRISPR/Cas9 sgRNA library bone marrow-bearing MM model, we found that hepatoma-derived growth factor (HRP2) was suppressor PIs its downregulation...
<h3>Aims</h3> To investigate the potential morphological alterations of grey and white matter in monocular amblyopic children using voxel-based morphometry (VBM) diffusion tensor imaging (DTI). <h3>Methods</h3> A total 20 age-matched controls were recruited. Whole-brain MRI scans performed after a series ophthalmologic exams. The data processed two-sample t-tests employed to identify group differences volume (GMV), (WMV) fractional anisotropy (FA). <h3>Results</h3> After image screening,...
Abstract Background To assess the efficacy and safety of tucidinostat plus exemestane as a neoadjuvant strategy in early-stage breast cancer. Methods This prospective, open-label, single-arm phase II trial enrolled patients with stage II-III cancer hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative. Eligible received exemestane, then breast-conserving surgery (BCS) or modified radical mastectomy. Results Among 20 patients, 3 them achieved preoperative...
The proteasome inhibitor is a target therapy for multiple myeloma (MM) patients, which has increased the overall survival rate of in clinic. However, relapse and toxicity are major challenges almost all MM patients. Thus, there an urgent need effective less toxic combination therapy. Here, we demonstrated that natural compound, resveratrol (RSV) displayed anti-proliferative activity dose- time-dependent manner panel cell lines. More importantly, low concentration RSV was synergistic with...
Abstract Ferroptosis has been demonstrated a promising way to counteract chemoresistance of multiple myeloma (MM), however, roles and mechanism bone marrow stromal cells (BMSCs) in regulating ferroptosis MM remain elusive. Here, we uncovered that were more susceptible ferroptotic induction under the interaction BMSCs using vitro vivo models. Mechanistically, elevated iron level cells, thereby activating steroid biosynthesis pathway, especially production lanosterol, major source reactive...
Multiple myeloma (MM) is an incurable malignancy of plasma cells. Ivermectin a US Food and Drug Administration-approved drug for antiparasitic use. Here, we showed that ivermectin exerted anti-MM effects significantly synergized with proteasome inhibitors in vitro vivo. alone exhibited mild activity vitro. Further investigation suggested inhibited the nucleus by repressing nuclear import subunits, such as PSMB5-7 PSMA3-4. Therefore, treatment caused accumulation ubiquitylated proteins...
The aims of this study were to observe the effects thalidomide on a rat model pulmonary fibrosis, determine protein expression levels phosphorylated c-Jun N-terminal kinase (p-JNK) and α-smooth muscle actin (α-SMA) explore mechanism underlying preventive effect fibrosis. Ninety healthy male Wistar rats (200±20 g) randomly divided into control (N), (M), SP600125 (SP), (T) plus (SP + T) groups. Pulmonary fibrosis models established in groups M, SP, T SP by intratracheal instillation bleomycin...
The oncogenic microRNA-21 contributes to the pathogenesis of multiple myeloma. Ibrutinib (also referred as PCI-32765), an inhibitor Bruton’s tyrosine kinase, while its effects on myeloma have not been well described. Here, we show that is marker closely linked with progression Moreover, ibrutinib attenuates expression in cells by inhibiting nuclear factor-κB and signal transducer activator transcription 3 signaling pathways. Taken together, our results suggest a promising potential treatment...
Purpose: To evaluate the detection of gene mutations in bone marrow biopsy and circulating free DNA (cfDNA) from plasma multiple myeloma (MM).Experimental design: We used cell-free to test BRAF V600, KRAS G12/G13, NRAS G12/G13 Q61 using multiplex assays for droplet digital PCR (ddPCR), evaluated results with clinical outcomes.Results: found 83 patients, detectable mutation frequencies above four genes were 4 (5%), 13 (16%), 3 (4%) 14 (17%) marrow, respectively.The median variant allelic...
Inositol polyphosphate-4-phosphatase type II (INPP4B) has been identified as a tumor suppressor, while little is known about its expression and function in multiple myeloma (MM). In this study, we evaluated the of INPP4B 28 cases newly diagnosed MM patients 42 extramedullary plasmacytoma (EMP) compared with normal plasma cells found that low was correlated poor outcomes patients. Moreover, seven cell lines all lower than cells. addition, loss promoted proliferation cells; however, gain...